MedTrace Logo

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

NCT06246110 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-11-12

No results posted yet for this study

Summary

This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.

Conditions

Interventions

DRUG

EIK1001

EIK1001 is a Toll like receptor 7/8 (TLR 7/8) agonist

DRUG

Pembrolizumab

PD-1 inhibitor

DRUG

Paclitaxel

Chemotherapy

DRUG

Pemetrexed

Chemotherapy

DRUG

Carboplatin

Chemotherapy

Sponsors & Collaborators

  • Eikon Therapeutics

    lead INDUSTRY

Principal Investigators

  • Etah Kurland, MD · Eikon Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-06
Primary Completion
2026-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06246110 on ClinicalTrials.gov